Press Releases

Cannasat Therapeutics now public on the TSX Venture Exchange

Canada Newswire, April 5, 2022

TORONTO, ONTARIO - (Canada Newswire – April 5, 2022) – Moses Znaimer, Chairman of Cannasat Therapeutics Inc. (“Cannasat”), is pleased to announce that the Company is now a public entity and is trading on the TSX Venture Exchange, under the symbol “CTH”. Management will be available for a press conference at 11:00am on Wednesday, April 5, 2022 at Ontario Investment Service, BCE Place, Canada Trust Tower, 161 Bay Street, Suite 4040, Toronto, Ontario.

“Cannasat is a pioneering effort into the therapeutic applications of marijuana,” says Mr. Znaimer. “The time has come to let Canadians know that Canada is at the forefront of research into cannabis and access to the medicines derived from it.”

For almost 2 years now, Cannasat has been a private company funded by forward thinking individuals. “Now investors have the opportunity to participate in the creation of a new class of drugs derived from this plant,” adds Cannasat CEO David Hill. “We believe these new medicines will have significant potential.”

Cannasat holds a minority stake in Prairie Plant Systems, the country’s only legal medical marijuana grower and distributor, which operates under the auspices of Health Canada; and is launching an education campaign to tell Canadians who suffer from diseases including Multiple Sclerosis, HIV-AIDS and Arthritis that they may qualify for the government’s medical marijuana program.



Present or available for Q&A following an opening statement will be:
Moses Znaimer, Chairman
David Hill, Chief Executive Officer
Umar Syed, Vice President, Scientific & Strategic Affairs
Andrew Williams, Vice President, Operations
Sara Lee Irwin, Director, Public Relations
(federally licensed medical marijuana patient)
Hilary Black, Director, Communications


For more information please contact:

Cannasat Therapeutics Inc.
Hilary Black
W: 416-703-2449 (ext. 245)
F: 416-703-8752
[email protected]


The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release.

Horizonatal Rule
About CynapsusLine SeperationAPL-130277 ProductLine SeperationParkinson's DiseaseLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2016, Cynapsus Therapeutics Inc.
All rights reserved.

Traded on